Skip to main content

Advertisement

Table 1 Several previous reports of salvage brachytherapy

From: Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report

Study year N Prior RT Use of ADT Median f/u Outcome Adverse event Prescribed dose
Koutrouveils* 2003 [1] 31 seed Neo 3 mos except 1 30 mos 5 yr-bDFS: 87% GI: G4 (2/31) 125I:100-144 Gy 103Pd:100-120 Gy
Wong 2006 [3] 17 EBRT Neo 3 mos: 12 ad 6 mos: 5 44 mos 4 yr-bDFS: 75% GU:G4 (1/17) 125I:126 Gy in principle
Nguyen 2007 [4] 25 EBRT: 13 seed: 12 none 47 mos 4 yr-bDFS: 70% GU: G3-4 13% GI: G3-4 30% 125I:137 Gy
Lee 2007 [5] 21 EBRT Concurrent -ad: 12 36 mos 5 yr-bDFS: 38% G3 or over: none 125I:90 Gy
Aaronson 2009 [6] 24 EBRT Concurrent: 17% 30 mos 3 yr-bDFS: 89.5% GU: G3 (1/24) 125I:144 Gy (108 Gy)
Moman 2010 [7] 31 EBRT: 20 seed: 11 Neo 3 mos: 5 9.2 yrs 5 yr-FFbF: 23% lateGU: G3 (6/31) lateGI: G3 (2/31) 125I:145 Gy
Burri* 2010 [2] 37 EBRT: 32 seed: 5 Neo + ad 6 mos: 31 86 mos 5 yr-FFbF: 64.5% GI: G4 (1/37) 125I:135 Gy
  1. *Report of brachytherapy for recurrence of seminal vesicle.
  2. RT: Radiation Therapy, ADT: Androgen Deprivation Therapy, f/u: follow-up, EBRT : External Beam Radiation Therapy, Seed: Seed Implant (Brachytherapy), Neo: Neoadjuvant Therapy, Ad: Adjuvant Therapy, bDFS: biochemical Disease Free Survival, FFbF: Freedom From biochemical Failure, GI: Gastrointestinal adverse effect, GU: Genitourinary adverse effect, G: Grade.